Carcinoid Tumors

Surgical Clinics of North America

Volumn 89, Issue 5, 2009, Pages 1123-1137

  Pasieka, Janice L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Carcinoid; Neuroendocrine tumors; Review; Treatment of prognosis

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PASIREOTIDE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; APPENDIX CARCINOID; CANCER CLASSIFICATION; CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLON CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; ENTEROCHROMAFFIN CELL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; HEMICOLECTOMY; HUMAN; LAPAROTOMY; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECTUM CARCINOID; REVIEW; STOMACH CARCINOID; STOMACH SURGERY; SURVIVAL RATE; TUMOR DIFFERENTIATION;

CARCINOID TUMOR; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS;

EID: 70349860278     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2009.06.008     Document Type: Review

References (54)

1. Oberndorfer S. Karzinoid tumore des Dunndarms. Frankf Z Pathol 1 (1907) 426-430 [in German]
2. Ransom W. A case of primary carcinoma of the ileum. Lancet 2 (2009) 1020-1023
3. Gosset A., and Masson P. Tumeurs endocrines se l'appendice. Presse Med 25 (2009) 237-240 [in Italian]
4. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 19 (2005) 491-505
5. Lembeck F. [Current status of carcinoid research; pharmacological report.]. Krebsarzt 13 (1958) 196-202 [in German]
6. Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3 (2003) 863-877
7. Dayal Y. Gl-NETs-uniform but also diverse. Endocr Pathol 18 (2007) 135-140
8. Van Eeden S., Quaedvlieg P.F., Taal B.G., et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 33 (2002) 1126-1132
9. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9 (2008) 61-72
10. Baudin E., Bidart J.M., Backelot A., et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12 (2001) S79-S82
11. Stivanello M., Berruti A., Torta M., et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 12 (2001) S73-S77
12. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 (2008) 3063-3072
13. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 (2003) 934-959
14. de Herder W.W. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Pract Res Clin Gastroenterol 19 (2005) 705-715
15. Akerstrom G., and Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21 (2007) 87-109
16. Granberg D., and Oberg K. Neuroendocrine tumours. Cancer Chemother Biol Response Modif 22 (2005) 471-483
17. Kloppel G., and Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 19 (2005) 507-517
18. Delle Fave G., Capurso G., Milione M., et al. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 19 (2005) 659-673
19. Bordi C., Caruana P., D'Adda T., et al. Smooth muscle cell abnormalities associated with gastric ECL cell carcinoids. Endocr Pathol 6 (1995) 103-113
20. Ruszniewski P., Delle Fave G., Cadiot G., et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 84 (2006) 158-164
21. Bendelow J., Apps E., Jones L.E., et al. Carcinoid syndrome. Eur J Surg Oncol 34 (2008) 289-296
22. Woodside K.J., Townsend C.M., and Mark E.B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 8 (2004) 742-756
23. Schindl M., Kaserer K., and Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg 136 (2001) 49-54
24. Rindi G., Luinetti O., Cornaggia M., et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104 (1993) 994-1006
25. Chambers A.J., Pasieka J.L., Dixon E., et al. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery 144 (2008) 645-651
26. Bernheim A.M., Connolly H.M., and Pellikka P.A. Carcinoid heart disease. Curr Treat Options Cardiovasc Med 9 (2007) 482-489
27. Bhattacharyya S., Davar J., Dreyfus G., et al. Carcinoid heart disease. Circulation 116 (2007) 2860-2865
28. Bhattacharyya S., Toumpanakis C., Caplin M.E., et al. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol 101 (2008) 378-381
29. Chambers A.P., Pasieka J.L., Dixon E., et al. The role of imaging studies in the staging of midgut neuroendocrine tumors. J Am Coll Surg 207 (2009) S18
30. Orlefors H., Sundin A., Garske U., et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90 (2005) 3392-3400
31. Pacak K., Eisenhofer G., and Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 25 (2004) 568-580
32. Givi B., Pommier S.J., Thompson A.K., et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 140 (2006) 891-897
33. Hellman P., Lundstrom T., Ohrvall U., et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26 (2002) 991-997
34. Boudreaux J.P., Putty B., Frey D.J., et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 241 (2005) 839-845
35. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445
36. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 (2003) 29-37
37. Eriksson J., Stalberg P., Nilsson A., et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32 (2008) 930-938
38. Osborne D.A., Zervos E.E., Strosberg J., et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13 (2006) 572-581
39. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (2005) 1590-1602
40. 111In-octreotide in patients with metastatic progressive neuroendocrine tumors. Surgery 136 (2004) 1218-1226
41. 131I mIBG in the management of metastatic midgut carcinoid tumors. World J Surg 28 (2004) 1157-1162
42. Taal B.G., Hoefnagel C.A., Valdes Olmos R.A., et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14 (1996) 1829-1838
43. 111 In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44 (2003) 1-6
44. Frilling A., Weber F., Saner F., et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140 (2006) 968-976
45. Kwekkeboom D.J., Mueller-Brand J., Paganelli G., et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 Suppl 1 (2005) 62S-66S
46. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43 (2002) 610-616
47. Zuetenhorst J.M., and Taal B.G. Metastatic carcinoid tumors: a clinical review. Oncologist 10 (2005) 123-131
48. Faiss S., Pape U.F., Bohmig M., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 (2003) 2689-2696
49. Engstrom P.F., Lavin P.T., Moertel C.G., et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2 (1984) 1255-1259
50. Bukowski R.M., Johnson K.G., Peterson R.F., et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60 (1987) 2891-2895
51. Delaunoit T., Neczyporenko F., Rubin J., et al. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol 103 (2008) 475-483
52. Papouchado B., Erickson L.A., Rohlinger A.L., et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 18 (2005) 1329-1335
53. Stinner B., and Rothmund M. Neuroendocrine tumours (carcinoids) of the appendix. Best Pract Res Clin Gastroenterol 19 (2005) 729-738
54. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 326 (1992) 519-523